A spin-out from the University of Oxford, Alethiomics is built on a decade of world-leading research on blood cancers and breakthrough innovation in single-cell multi-omic analysis by founders Professor Adam Mead and Professor Beth Psaila, both academic clinicians and expert haematologist. The company's novel therapeutics, based on targets discovered using the TARGET-seq platform, will be developed to address the unmet needs in blood cancers.
Alethiomics is backed by £6M seed financing from science business builder Oxford Science Enterprises. Its foundational research has been supported by academic and charitable grants, including the support of Cancer Research UK, which has become a minority shareholder in the company.
Co-founders Adam and Beth will act as consultants to Alethiomics and serve on the Scientific Advisory Board whilst continuing to lead their research groups at the MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, the University of Oxford, alongside their clinical practices in the Department of Haematology at Oxford University Hospitals NHS Trust.
Chairman Dr Mark Throsby is a biopharmaceutical executive with extensive research experience and a track record of innovation and execution. He is an expert in antibody engineering and immunology with over two decades of commercial experience gained in pharma and biotech at Crucell NV and Merus NV. Alongside his role at Alethiomics, he acts as COO/CSO of Gadeta BV and serves on the Board of Ona Therapeutics.
CSO Dr Ed Ainscow brings two decades of experience working on innovative approaches to early drug discovery in pharma and biotech. He joins from Carrick Therapeutics Ltd where he has been Chief Technology Officer for the past five years.